Consensus $723.85M. Preliminary unaudited free cash flow was approximately negative $84M for the fourth quarter of 2024, and approximately negative $275M for the full year 2024. Cash, cash equivalents, restricted cash and marketable debt securities were $944M as of December 31, 2024. “We are extremely pleased with the strong traction and support we saw in the first full quarter of commercial launch of Shield. Given this success, we are focused on rapidly growing our commercial infrastructure to capture the massive opportunity ahead. We look forward to achieving additional milestones in 2025 as we continue driving innovation and growth in our screening business,” said AmirAli Talasaz, co-founder and co-CEO.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $45 from $40 at Bernstein
- Guardant Health Shield test selected for use in NCI Vanguard study
- Guardant Health enters partnership with MiBA
- Guardant Health and COTA partner in advanced oncology R&D
- Guardant Health announces collaboration with Boehringer Ingelheim